share_log

What Analysts Are Saying About Vertex Pharmaceuticals Stock

Benzinga ·  Oct 1 08:01

15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:VRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings55401
Last 30D00100
1M Ago00100
2M Ago34100
3M Ago21101

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $500.53, a high estimate of $600.00, and a low estimate of $376.00. Witnessing a positive shift, the current average has risen by 8.29% from the previous average price target of $462.20.

1727784076_0.png

Breaking Down Analyst Ratings: A Detailed Examination

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment